Hans van Houte - Jan 19, 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Financial Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Hans van Houte
Stock symbol
NRIX
Transactions as of
Jan 19, 2022
Transactions value $
$0
Form type
4
Date filed
1/21/2022, 03:16 PM
Next filing
May 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +104K $0.00 104K Jan 19, 2022 Common Stock 104K $19.49 Direct F1
transaction NRIX Restricted Stock Units Award $0 +46.2K $0.00 46.2K Jan 19, 2022 Common Stock 46.2K $0.00 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F4 RSUs do not expire; they either vest or are canceled prior to the vest date.